Switzerland · 
What does Nextech Invest invest in?
Nextech Invest invests most often at Series B and Series C (92% of the rounds on record), in sectors such as Biomarker, Bioimaging and In Vitro Diagnostics.
Nextech Invest highlights
- 01
2 cheques in the last 12 months
- 02
Mostly Series B and Series C: 92% of its rounds
- 03
Led 3 rounds
What they do
we fuel the success of emerging biotechnology companies worldwide by identifying transformative cancer medicines.From their own website
- Type
- Private equity (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- BiomarkerBioimagingIn Vitro Diagnostics
- Based in
- Zurich, Switzerland
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first15 appearances
- 2026
2 rounds
- Oct
- Aug
- 2019
5 rounds
- Dec
- Nov
- Nov
- Jul
- Apr
- 2018
1 round
- Oct
- 2017
1 round
- Dec
- 2016
1 round
- Aug
- 2015
2 rounds
- Apr
- Mar
- 2014
3 rounds
- Sept
- May
- Jan
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration5 named
ASAlfred ScheideggerManaging PartneriForm ADV
JHJakob Henrik LovenManaging PartneriForm ADV
MCMarco Christian WeibelChief Compliance Officer and Chief Financial OfficeriForm ADV
RJRocco Joseph SgobboManaging Partner and Chief Operating OfficeriForm ADV
TSThilo SchroederManaging PartneriForm ADV
We also hold 19 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$2.0Bgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Nextech Invest LTD.
- SEC number
- CRD 322629
What they claim to have backed
From their own portfolio page (on their website)
40 of 45 we have independently watched raise
ARS PharmaceuticalsAiRNAAlpha-9 OncologyAlterome TherapeuticsAlumisArvinasAtavistik BioAttovia TherapeuticsBe BiopharmaBlack Diamond Therapeutics, IncBlueprint MedicinesBoundless BioC4 TherapeuticsCircle PharmaCleave BiosciencesContext TherapeuticsCullinan TherapeuticsEQRxExo TherapeuticsHexagon BioIconOVir BioIdeaya BiosciencesKhartis TherapeuticsKinnate BiopharmaKronos BioKuraoncologyMariana OncologyMersana TherapeuticsNeon TherapeuticsORIC PharmaceuticalsPMV PharmaParabilis MedicinesPeloton TherapeuticsProfoundBioSilence TherapeuticsTYRA BiosciencesTubulisTurning Point Therapeutics,Vividion TherapeuticsZymeworksA2 BiotherapeuticsAutolus Therapeutics plcITMLaronde BioSail Biomedicines
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.